News & Trends - MedTech & Diagnostics
A healthcare sector gap in ESG reporting should be a wake-up call

The Australian healthcare sector is one of the lower performers in environmental, social and governance (ESG) reporting, according to Australia’s peak body on climate and health, the Climate and Health Alliance (CAHA).
While ASX200 companies increasingly acknowledge ESG performance as a value driver within their businesses, the ESG Reporting Trends report revealed that out of the 14 ASX200 companies in the healthcare sector none had a ‘comprehensive’ ESG reporting rating and only 5 had a ‘detailed’ reporting rating, highlighting a sector-wide gap.
CEO of the Climate and Health Alliance, Roland Sapsford, said “The revelation that the healthcare sector is lagging behind mining companies, utilities, and real estate sectors in reporting on serious ESG risks is deeply concerning.
“We all experienced the anxiety of not knowing how supply chain disruptions could affect everyday goods during the pandemic. Many people’s health was also potentially at risk with shortages of medications highlighting how important it is for the sector to manage these risks.”
Emerging ESG trends impacting the medtech sector
Among the fourteen (14) ASX 200 companies in the healthcare sector, Ansell, Fisher & Paykel Healthcare, Nanosonics, Ramsay Health Care and Sonic Healthcare had a ‘detailed’ reporting rating – the highest rating in the healthcare sector – while the remaining none (9) companies had moderate-basic ESG reporting ratings, with three (3) companies not reporting at all.
Mr Sapsford continued “The health sector continues to operate under considerable strain, the health workforce is struggling, and we continue to face unexpected and unprecedented challenges from extreme weather conditions.
“The idea that the health sector, of all sectors, is lacking transparency around how it manages risks – whether to supply chains, workforce, the pandemic or climate change – should send shock waves through the community and lead investors to ask hard questions.”
Reimagining healthcare across the entire patient journey: Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change in healthcare.
The content on Health Industry Hub is copyright protected and can only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.
News & Trends - Pharmaceuticals

A strategic alignment for HTA Review: Professor Skerritt appointed to Medicines Australia Board
Pharma News: Professor John Skerritt has been appointed as an Independent Selected Director on the Medicines Australia Board effective 4 […]
MoreNews & Trends - MedTech & Diagnostics

Breath of change: Cystic Fibrosis Australia forges pioneering partnership with local medtech
MedTech & Diagnostics News: In a move aimed at enhancing cystic fibrosis (CF) care and support, Australian-based medical device company, […]
MoreNews & Trends - Pharmaceuticals

Does the evidence support safety concerns following CAR-T cell therapies?
Pharma News: The U.S. Food and Drug Administration (FDA) has launched an investigation into a concerning risk associated with CAR-T […]
More